TL;DR: Ochre Bio does not publish a price list we can verify, which is normal for Healthcare companies at this stage. Below: what we can confirm, how to get a real quote, and 8 comparable tools to benchmark the number against.
What is verifiable about Ochre Bio pricing, how to get a real quote, and 8 comparable tools to price it against.
Last verified:
Not in any source we can verify. Ochre Bio is a Y Combinator-backed Healthcare company from the Winter 2020 batch, and companies at this stage usually quote per customer rather than publish rate cards. We will not guess at a number — anything quoted elsewhere without a source is guesswork too. The company profile we work from is the Y Combinator listing; the current figure has to come from Ochre Bio directly.
These are the closest comparable tools, matched on what Ochre Bio actually does. Price each one alongside it — stage and team size are a reasonable proxy for where a vendor sits on price.
| Compare against | What it does | Stage | Team |
|---|---|---|---|
| Biocogniv | — | YC Summer 2020 | 6 |
| Docbot | — | YC Winter 2019 | — |
| Excepgen | — | YC Winter 2019 | 3 |
| Mind Emulation Foundation | — | YC Winter 2018 | 1 |
| Gerostate Alpha | Developing novel therapeutics for aging and chronic disease | YC Summer 2018 | 6 |
| Serna Bio | Genetic Medicine with Small Molecules | YC Winter 2021 | 5 |
| Asher Bio | We build better immunotherapies | YC Summer 2019 | 3 |
| Ansa Biotechnologies | Next-generation DNA synthesis using enzymes | YC Winter 2020 | 72 |
That depends on a number we cannot see, so judge it on what we can: Ochre Bio is currently Active with a team of around 50. A small team means faster support and more negotiating room, but more risk of the product changing direction. A larger or public vendor costs more and moves slower. If price is the deciding factor, the earlier-batch companies in the table are usually the ones still competing on it.
See all Ochre Bio alternatives compared →
Built by LemStudio
Loading interactive view…